Clinical Trials Logo

Bone Metastases clinical trials

View clinical trials related to Bone Metastases.

Filter by:

NCT ID: NCT01417403 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases

Start date: August 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of hydroxychloroquine in treating patients with solid tumors undergoing radiation therapy for bone metastases. Drugs, such as hydroxychloroquine, may make tumor cells more sensitive to radiation therapy

NCT ID: NCT01231347 Terminated - Cancer Clinical Trials

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

GAMMA
Start date: April 2011
Phase: Phase 3
Study type: Interventional

AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival. Gemcitabine is administered on days 1, 8 and 15 of a 28 day cycle, AMG 479 or placebo is administered on days 1 and 15 of the 28 day cycle, both are administered intravenously. The primary purpose of the study is to determine if AMG 479 and gemcitabine improves overall survival as compared to placebo and gemcitabine.

NCT ID: NCT00981578 Terminated - Bone Metastases Clinical Trials

ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Start date: September 2009
Phase: N/A
Study type: Interventional

A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.

NCT ID: NCT00757757 Terminated - Prostate Cancer Clinical Trials

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Start date: September 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

NCT ID: NCT00019695 Terminated - Bone Metastases Clinical Trials

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Start date: March 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium. PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.